Cardiac injury and sustained cardiovascular abnormalities in long-COVID syndrome,i.e.post-acute sequelae of coronavirus disease 2019(COVID-19)have emerged as a debilitating health burden that has posed challenges for ...Cardiac injury and sustained cardiovascular abnormalities in long-COVID syndrome,i.e.post-acute sequelae of coronavirus disease 2019(COVID-19)have emerged as a debilitating health burden that has posed challenges for management of pre-existing cardiovascular conditions and other associated chronic comorbidities in the most vulnerable group of patients recovered from acute COVID-19.A clear and evidence-based guideline for treating cardiac issues of long-COVID syndrome is still lacking.In this review,we have summarized the common cardiac symptoms reported in the months after acute COVID-19 illness and further evaluated the possible pathogenic factors underlying the pathophysiology process of long-COVID.The mechanistic understanding of how Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2)damages the heart and vasculatures is critical in developing targeted therapy and preventive measures for limiting the viral attacks.Despite the currently available therapeutic interventions,a considerable portion of patients recovered from severe COVID-19 have reported a reduced functional reserve due to deconditioning.Therefore,a rigorous and comprehensive cardiac rehabilitation program with individualized exercise protocols would be instrumental for the patients with long-COVID to regain the physicalfitness levels comparable to their pre-illness baseline.展开更多
Myocarditis is a rare cardiomyocyte inflammatory process,typically caused by viruses,with potentially devastating cardiac sequalae in both competitive athletes and in the general population.Investigation into myocardit...Myocarditis is a rare cardiomyocyte inflammatory process,typically caused by viruses,with potentially devastating cardiac sequalae in both competitive athletes and in the general population.Investigation into myocarditis prevalence in the Coronavirus disease 2019(COVID-19)era suggests that infection with Severe acute respiratory syndrome coronavirus(SARS-CoV-2)is an independent risk factor for myocarditis,which is confirmed mainly through cardiovascular magnetic resonance imaging.Recent studies indicated that athletes have a decreased risk of myocarditis after recent COVID-19 infection compared to the general population.However,given the unique nature of competitive athletics with their frequent participation in high-intensity exercise,athletes possess distinct factors of susceptibility for the development of myocarditis and its subsequent severe cardiac complications(e.g.,sudden cardiac death,fulminant heart failure,etc.).Under this context,this review focuses on comparing myocarditis in athletes versus non-athletes,owing special attention to the distinct clinical presentations and outcomes of myocarditis caused by different viral pathogens such as cytomegalovirus,Epstein-Barr virus,human herpesvirus-6,human immunodeficiency virus,and Parvovirus B19,both before and after the COVID-19 pandemic,as compared with SARS-CoV-2.By illustrating distinct clinical presentations and outcomes of myocarditis in athletes versus non-athletes,we also highlight the critical importance of early detection,vigilant monitoring,and effective management of viral and non-viral myocarditis in athletes and the necessity for further optimization of the return-to-play guidelines for athletes in the COVID-19 era,in order to minimize the risks for the rare but devastating cardiac fatality.展开更多
文摘Cardiac injury and sustained cardiovascular abnormalities in long-COVID syndrome,i.e.post-acute sequelae of coronavirus disease 2019(COVID-19)have emerged as a debilitating health burden that has posed challenges for management of pre-existing cardiovascular conditions and other associated chronic comorbidities in the most vulnerable group of patients recovered from acute COVID-19.A clear and evidence-based guideline for treating cardiac issues of long-COVID syndrome is still lacking.In this review,we have summarized the common cardiac symptoms reported in the months after acute COVID-19 illness and further evaluated the possible pathogenic factors underlying the pathophysiology process of long-COVID.The mechanistic understanding of how Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2)damages the heart and vasculatures is critical in developing targeted therapy and preventive measures for limiting the viral attacks.Despite the currently available therapeutic interventions,a considerable portion of patients recovered from severe COVID-19 have reported a reduced functional reserve due to deconditioning.Therefore,a rigorous and comprehensive cardiac rehabilitation program with individualized exercise protocols would be instrumental for the patients with long-COVID to regain the physicalfitness levels comparable to their pre-illness baseline.
文摘Myocarditis is a rare cardiomyocyte inflammatory process,typically caused by viruses,with potentially devastating cardiac sequalae in both competitive athletes and in the general population.Investigation into myocarditis prevalence in the Coronavirus disease 2019(COVID-19)era suggests that infection with Severe acute respiratory syndrome coronavirus(SARS-CoV-2)is an independent risk factor for myocarditis,which is confirmed mainly through cardiovascular magnetic resonance imaging.Recent studies indicated that athletes have a decreased risk of myocarditis after recent COVID-19 infection compared to the general population.However,given the unique nature of competitive athletics with their frequent participation in high-intensity exercise,athletes possess distinct factors of susceptibility for the development of myocarditis and its subsequent severe cardiac complications(e.g.,sudden cardiac death,fulminant heart failure,etc.).Under this context,this review focuses on comparing myocarditis in athletes versus non-athletes,owing special attention to the distinct clinical presentations and outcomes of myocarditis caused by different viral pathogens such as cytomegalovirus,Epstein-Barr virus,human herpesvirus-6,human immunodeficiency virus,and Parvovirus B19,both before and after the COVID-19 pandemic,as compared with SARS-CoV-2.By illustrating distinct clinical presentations and outcomes of myocarditis in athletes versus non-athletes,we also highlight the critical importance of early detection,vigilant monitoring,and effective management of viral and non-viral myocarditis in athletes and the necessity for further optimization of the return-to-play guidelines for athletes in the COVID-19 era,in order to minimize the risks for the rare but devastating cardiac fatality.
